CDCA4 is aberrantly regulated in various cancers, comprising triple-negative breast cancer (BC), Wilm’s tumour, melanoma, and osteosarcoma, and is associated with poor patient outcomes (13, 25–28). This evidence concerns the gene CDCA4 and cancer.